Last mentioned: Feb 27, 2026
Committee Review
Expected date for health select committee to begin detailed scrutiny of the bill.
Draft Law Unveiled
The Rare Cancers Law is formally introduced as a draft to Parliament.
Official Reporting
MHRA and GOV.UK release data confirming the surge in neurotech and AI testing activity.
Record Achievement
Total CINs for the year reach 137, a new historical high for the agency.
Policy Consultation
UK Government opens consultation on rare disease frameworks.
IDAP Expansion
The MHRA expands the Innovative Devices Access Pathway to include more AI-driven startups.
Baseline Growth
UK concludes 2024 with 104 clinical investigation notifications.
Advocacy Surge
Brain tumor charities increase lobbying efforts for legislative reform.
The UK government is advancing a draft Rare Cancers Law designed to fast-track treatments and research for patients with incurable brain tumors. This legislative push aims to dismantle bureaucratic barriers that have historically hindered drug development and clinical trial access for rare oncological conditions.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) reported a record 137 clinical investigation notifications in 2025, a 32% increase over the previous year. This surge is driven by a strategic regulatory pivot toward AI-driven diagnostics and brain-computer interfaces, signaling the UK's intent to lead in high-risk medical innovation.
This page surfaces every story mentioning MHRA across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where MHRA was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |